
Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug
Sandoz Group AG SDZNY SDZXF on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. AMGN for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel (etanercept), first approved by the U.S. Food and Drug …